Specifically, our study demonstrates that miR‐124 can inhibit stem‐like properties and enhance radiosensitivity by directly targeting JAMA in NPC, suggesting that miR‐124 has potential value for diagnosis and as a therapeutic target in NPC. This evidence concerns the gene F11R and nasopharyngeal carcinoma.